



PATENT  
Attorney Docket No.: 01142.0122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
PAUSCH, Mark H. et al. )  
)  
Application No.: 08/816,011 ) Group Art Unit: 1646  
)  
Filed: March 11, 1997 ) Examiner: M. PAK  
)  
For: POTASSIUM CHANNELS, NUCLEOTIDE )  
SEQUENCES ENCODING THEM, AND )  
METHODS OF USING SAME )

Assistant Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821 - 1.825**

Sir:

In connection with the Sequence Listing submitted herewith, the undersigned hereby states that:

1. The submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not contain any new matter;
2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
3. All statements made herein on the undersigned's knowledge are true, and all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

LAW OFFICES


FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

Code, and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Matthew T. Latimer  
Reg. No. 44,024  
(202) 408-4495  
[matthew.latimer@finnegan.com](mailto:matthew.latimer@finnegan.com)

Date: June 11, 2001